Table 1.
Some clinical and thyroidal data evaluated. The numbers of women in whom the given parameters were available are reported in brackets. Comparison was made between women with normal thyroid function and women on L-T4 therapy. Other drugs were: spironolactone (n = 2), dopamine-antagonist (n = 2), steroids (n = 2), rizatriptan (n = 1), and hydroxychloroquine (n = 1)
| All women (n = 250) | Women with normal thyroid function (n = 171) | Women on L-T4 therapy (n = 79) | Significance P |
|
|---|---|---|---|---|
| Age (year); mean ± SD | 34.1 ± 9.9 | 31.5 ± 9.2 | 39.7 ± 9.5 | < 0.0001 |
| BMI (kg/m2); median, IQR, Cl |
22.2; 20.2-25.6 21.5-22.9 |
21.7; 19.9-25.2 21.1-22.6 |
23.5; 21.2-26.6 21.9-22.4 |
0.03 |
| Non-smokers (%) | 71% (116) | 72% (90) | 54% (26) | 0.01 |
| Former/current smokers (%) | 29% (47) | 28% (25) | 46% (22) | |
| TSH (mIU/l); median, IQR, Cl |
2.00; 1.28-2.84 1.84-2.23 |
2.08; 1.35-2.83 1.87-2.30 |
1.84; 1.05-2.85 1.48-2.17 |
0.11 |
| f-T4 (pmol/l); median, IQR, Cl |
13.4; 11.5-15.7 13.0-14.0 |
12.9; 11.1-14.7 12.4-13.3 |
15.2; 12.8-17.6 14.0-16.2 |
< 0.0001 |
| L-T4 (μg/day); median, IQR, Cl | – | – |
60.0; 50.0-90.7 57.1-75.0 |
|
| TPOAb positive (%) | 43% (166) | 20% (96) | 66% (70) | < 0.0001 |
| TV (ml); median, IQR, Cl | 7.9; 6.4-10.6 (215) 7.4-8.4 | 7.9; 6.6-10.3 (151) 7.6-8.5 | 8.0; 5.4-12.1 (64) 6.2-9.5 | |
| Other ongoing drugs (number) none | 124 | 91 | 33 | |
| vitamin D/other vitamins | 27 | 14 | 13 | |
| hormonal contraceptives | 28 | 21 | 7 | |
| psychotropic drugs | 23 | 13 | 10 | |
| cabergoline | 17 | 13 | 4 | |
| metformin | 8 | 6 | 2 | |
| anti-secretive drugs | 7 | 2 | 5 | |
| H1- inhibitors drugs | 5 | 4 | 1 | |
| statins | 3 | 2 | 1 | |
| other drugs | 8 | 7 | 1 |